Ace Vision Group closes $13.3 million in funding for laser development
Click Here to Manage Email Alerts
Ace Vision Group closed a Series A preferred stock round totaling $13.3 million to continue development of its VisioLite ophthalmic laser for the treatment of age-related vision dysfunction, according to a press release.
Robert Picerne of Picerne Group LLC led the funding round.
“This funding round validates Ace Vision Group’s path forward to explore the potential of laser microporation technologies, a new frontier in eye therapy,” AnnMarie Hipsley, DPT, PhD, founder and CEO of Ace Vision Group, said in the release. “Our focus is to provide a first-in-class novel therapeutic technology to address and potentially prevent numerous age-related dysfunctions of the eye, which lead to functional vision loss. We are excited to bring this therapeutic technology to patients suffering from presbyopia, which is a vast market with a large unmet need.”
Ace Vision Group is also in preclinical development of a minimally invasive laser scleral microporation rejuvenation procedure for patients with presbyopia, glaucoma and other eye diseases, the release said.
Read more about
Click Here to Manage Email Alerts